Loading…
Vogenx, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VOGX.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| TCMDTactile Systems Technology Inc | $22.43 | 21.0x | 2.3x | — | 11.88% | $508.09M |
| KMDAKamada Ltd | $8.87 | 23.3x | 1.9x | 4.74% | 8.40% | $511.89M |
| ARVNArvinas Inc | $7.83 | 30.1x | 0.9x | — | 1.59% | $511.97M |
| RGNXREGENXBIO Inc. | $7.50 |
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Company description provided by Yahoo Finance.
| — |
| 5.7x |
| — |
| -137.63% |
| $495.1M |
| NPCENeuroPace Inc | $14.41 | — | 41.5x | — | -103.27% | $494.61M |
| KYTXKyverna Therapeutics, Inc. | $8.37 | — | 2.6x | — | -87.24% | $517.63M |